Finch is cutting 37% of its workforce days after Takeda returned two preclinical assets back to the microbiome-focused biotech. The company is also pausing clinical trial plans of its treatment for autism spectrum disorder.

AnaptysBio’s stuttering effort to rebuild its pipeline around imsidolimab has hit another setback. After flopping in palmoplantar pustulosis and acne, the anti-IL-36 receptor antagonist has failed to move the needle in the chronic skin disease hidradenitis suppurativa, leading the biotech to stop work on one indication and plan to out-license the asset.

Mereo BioPharma, under pressure from an activist investor, has reduced its head count to stretch its cash runway out into the second quarter of 2025. The biotech disclosed the cuts in a rebuttal to Rubric Capital Management’s “low-risk strategy” for unlocking the value of its assets while preserving cash.

Scientists revealed a link between chronic pain and lung cancer—a link that also offers a potentially druggable pathway for both conditions, according to new research conducted in mouse models.

Just a few short months after liftoff, Sanofi’s drug ingredients spinoff EUROAPI has started to show its promise as a standalone company. For the first half of 2022, the company generated 483.8 million euros (about $483.2 million) in revenue.

Despite the hype around adoptive T-cell therapies, it’s still a challenge to find therapeutic targets that are consistent across tumor types and aren’t expressed in healthy cells. Now, a team of scientists working with immunotherapy drug development biotech Immatics has identified an antigen component that checks both of those boxes.

Just hours before outgoing AstraZeneca executive Chris Sheldon was set to take up his post at crosstown rival GSK, a judge has ordered a temporary injunction.

Fresh off reporting the promising results of a phase 3 study of its constipation relief device, Vibrant Gastro is keeping things moving.

Messages on the popular social media site accused the retail pharmacy of “putting politics over patients" by refusing to fill a prescription for non-abortion related care. Other drugstores restricting reproductive health care raise questions about retail’s role in the abortion debate.

Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members

ZS helps life sciences companies shape the future of medicine by turning healthcare data into transformative insights. Discover the power of R&D innovation

Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases.

Improve your congress competitive intelligence and cut down costs by 50%

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.